PTPN22-IN-1 |
Katalog-Nr.GC63553 |
PTPN22-IN-1 ist ein potenter PTPN22-Inhibitor (IC50=1,4 μM; Ki=0,50 μM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2580935-57-3
Sample solution is provided at 25 µL, 10mM.
PTPN22-IN-1 is a potent PTPN22 inhibitor (IC50=1.4 µ Ki=0.50 µM). PTPN22-IN-1 exhibits >7-10 fold selectivity for PTPN22 over similar phosphatases. PTPN22-IN-1 augments antitumor immune responses[1]. From WO2021007491A1 compound L-1.
PTPN22-IN-1 (Compound L-1) (WT mice; intraperitoneally) significantly reduces MC38 tumor growth. PTPN22-IN-1 (syngeneic immunocompetent model; CT26 in Balb/c mice) shows similar antitumor effects[1].Administration of L-l intraperitoneally at 10 mg/kg yielded an average AUC of 4.55 µM h and Cmax of 1.1 1 µM (Fig. 9d), which is more than twice of its Ki value[1].
PTPN22-IN-1 (Compound L-1) (WT mice; intraperitoneally) significantly reduces MC38 tumor growth. PTPN22-IN-1 (syngeneic immunocompetent model; CT26 in Balb/c mice) shows similar antitumor effects[1].Administration of L-l intraperitoneally at 10 mg/kg yielded an average AUC of 4.55 µM h and Cmax of 1.1 1 µM (Fig. 9d), which is more than twice of its Ki value[1].
[1]. Elizabeth Jaffee, et al. Targeting ptpn22 in cancer therapy. WO2021007491A1.
Average Rating: 5
(Based on Reviews and 19 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *